Minghui Pharmaceutical (Hangzhou) Ltd
Quick facts
Phase 3 pipeline
- Furmonertinib · Other
- MH004 Ointment · Dermatology
MH004 is a topical ointment formulation designed to treat dermatological conditions through localized therapeutic action. - MHB018A injection
MHB018A injection's mechanism is not publicly available.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Minghui Pharmaceutical (Hangzhou) Ltd portfolio CI brief
- Minghui Pharmaceutical (Hangzhou) Ltd pipeline updates RSS
Frequently asked questions about Minghui Pharmaceutical (Hangzhou) Ltd
What is Minghui Pharmaceutical (Hangzhou) Ltd's pipeline?
Minghui Pharmaceutical (Hangzhou) Ltd has 3 drugs in Phase 3, 0 in Phase 2, 7 in Phase 1. Late-stage candidates include Furmonertinib, MH004 Ointment, MHB018A injection.
Related
- Sector hub: All tracked pharma companies